The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
Open accessAbstract
OBJECTIVES: To investigate the screening performance of measuring blood pressure and other variables in identifying those who will develop, or die from, ischaemic heart disease and stroke. To quantify by how much drugs that lower blood pressure will reduce the risk of ischaemic heart disease and stroke in those designated 'screen positive'. DATA SOURCES: MEDLINE, Cochrane collaboration and Web of Science databases; Stroke registries; Health Survey for England; Office of National Statistics; BUPA (British United Provident Association) study. REVIEW METHODS: Relevant cohort studies and randomised trials were identified and analysed. Statistical analysis was used to determine drug efficacy and adverse effects. RESULTS: Lowering blood pressure by 5 mmHg diastolic reduces the risk of stroke by an estimated 34% and ischaemic heart disease by 21% from any pre-treatment level; there is no threshold. These estimates, from cohort studies, have been corroborated by the results of randomised trials in persons with high, average and below average levels of blood pressure. In spite of its importance in causing cardiovascular disease blood pressure is a poor predictor of cardiovascular events. Its poor screening performance is illustrated by the findings that in the largest cohort study, persons in the top 10% of the distribution of systolic blood pressure experienced only 21% of all ischaemic heart disease events and 28% of all strokes at a given age. Combining several reversible risk factors adds little to the screening performance of blood pressure alone; for example the 25% of men aged 5564 at highest computed risk (> or =1%) experience only 46% of all ischaemic heart disease events. The main methods of screening should be to identify all persons with a history of cardiovascular disease events (for example identifying patients at the time of hospital discharge following a first myocardial infarction detects 50% of all heart disease deaths in a population at a false positive rate of 12%), and to use a person's age. Identifying everyone with a history of myocardial infarction or stroke in a population and everyone aged 55 or more would include 98% of all deaths from ischaemic heart disease and stroke. The five main categories of blood pressure lowering drugs, thiazides, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists and calcium channel blockers, significantly reduce blood pressure from all pre-treatment levels though the extent of the blood pressure reduction increased with pre-treatment blood pressure. The reductions were similar at standard dose for the five categories; average reduction was 9.1 systolic and 5 diastolic. The effect of combinations of two drugs on blood pressure was additive. No effect of age was apparent, given blood pressure. There were no serious metabolic consequences of using these drugs in standard dose. CONCLUSIONS: The evidence presented indicates that three drugs in combination may reduce stroke by about two-thirds and ischaemic heart disease by half. The report suggests that the term hypertension should be avoided because it is not a disease and it implies another category (normotensives) who would not benefit from lowering blood pressure. Blood pressure reduction using combinations of safe, well-established drugs is effective in preventing cardiovascular events. It is therefore suggested that such preventive therapy be considered more widely in people who by virtue of existing disease or simply age are at risk of a heart attack or stroke regardless of initial blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Køber, L., Torp-Pedersen, C., Carlsen, J. E., Bagger, H., Eliasen, P., Lyngborg, K., Videbæk, J., Cole, D. S., Auclert, L., Pauly, N. C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332503 · Cited by 1,773
AMERY, A. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91783-0 · Cited by 1,476
Medical Research Council trial of treatment of hypertension in older adults: principal results.
Peart, S., Brennan, P. J., Broughton, P., Dollery, C. T., Hudson, M. F., Lever, A. F., Meade, T. W., Rose, G., & Pocock, S. (1992) · Cited by 1,360
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Self-citationHypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
The Strategy of Preventive Medicine
Rose, G. (1993) · doi:10.1093/oso/9780192624864.001.0001 · Cited by 1,069
Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks: US Population Data
Stamler, J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410050036006 · Cited by 1,015
Effects of Oral Potassium on Blood Pressure: Meta-analysis of Randomized Controlled Clinical Trials
Whelton, P. K. (1997) · JAMA · doi:10.1001/jama.1997.03540440058033 · Cited by 1,010
Sudlow, C. L. M., & Warlow, C. P. (1997) · Stroke · doi:10.1161/01.str.28.3.491 · Cited by 885
(1995) · The Lancet · doi:10.1016/s0140-6736(95)92836-7 · Cited by 856
Asymptomatic hyperuricemia. Risks and consequences in the normative aging study
Campion, E. W., Glynn, R. J., & Delabry, L. O. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90441-4 · Cited by 851
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 825
ANGIOTENSIN-CONVERTING ENZYME AND THE COUGH REFLEX
Morice, A., Brown, M., Lowry, R., & Higenbottam, T. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91547-9 · Cited by 746
Blood Pressure Lowering Treatment Trialists’ Collaboration
Neal, B. C. (2001) · Cited by 685
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events
Pitt, B., Byington, R. P., Furberg, C. D., Hunninghake, D. B., Mancini, G. B. J., Miller, M. E., Riley, W., & (for the PREVENT Investigators) (2000) · Circulation · doi:10.1161/01.cir.102.13.1503 · Cited by 669
BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE
Cruickshank, J., Thorp, J., & Zacharias, F. J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90231-5 · Cited by 656
Blood pressure and cardiovascular disease in the Asia Pacific region
(2003) · Journal of Hypertension · doi:10.1097/00004872-200304000-00013 · Cited by 644
Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989.
Brown, R. D., Whisnant, J. P., Sicks, J. D., O’Fallon, W. M., & Wiebers, D. O. (1996) · PubMed · Cited by 639
Ramsay, L., Williams, B., Johnston, G., MacGregor, G., Poston, L., Potter, J., Poulter, N., Russell, G., & for the British Hypertension Society (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000917 · Cited by 585
Krum, H., Viskoper, R. J., Lacourciere, Y., Budde, M., & Charlon, V. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381202 · Cited by 570
(1970) · JAMA · doi:10.1001/jama.213.7.1143 · Cited by 554
Survival and recurrence following stroke. The Framingham study.
Sacco, R. L., Wolf, P. A., Kannel, W. B., & McNamara, P. M. (1982) · Stroke · doi:10.1161/01.str.13.3.290 · Cited by 543
Blood pressure, cholesterol, and stroke in eastern Asia
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03454-0 · Cited by 512
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy
Svensson, P., de Faire, U., Sleight, P., Yusuf, S., & Östergren, J. (2001) · Hypertension · doi:10.1161/hy1101.099502 · Cited by 491
Grimm, R. H., Grandits, G. A., Prineas, R. J., McDonald, R. H., Lewis, C. E., Flack, J. M., Yunis, C., Svendsen, K., Liebson, P. R., Elmer, P. J., et al. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.8 · Cited by 465
Beta-Blockers Versus Diuretics in Hypertensive Men: Main Results from the HAPPHY Trial
Wilhelmsen, L., Berglund, G., Elmfeldt, D., Fitzsimons, T., Holzgreve, H., Hosie, J., H??rnkvist, P.-E., Pennert, K., Tuomilehto, J., & Wedel, H. (1987) · Journal of Hypertension · doi:10.1097/00004872-198710000-00009 · Cited by 463
Use of ramipril in preventing stroke: double blind randomised trial
Bosch, J., Yusuf, S., Pogue, J., Sleight, P., Lonn, E., Rangoonwala, B., Davies, R., Ostergren, J., & Probstfield, J. (2002) · BMJ · doi:10.1136/bmj.324.7339.699 · Cited by 420
Wikstrand, J. (1988) · JAMA · doi:10.1001/jama.259.13.1976 · Cited by 408
Ellerbeck, E. F. (1995) · JAMA · doi:10.1001/jama.1995.03520430045037 · Cited by 374
Clinical Profile of Angioedema Associated With Angiotensin Converting-Enzyme Inhibition
Slater, E. E. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410070095035 · Cited by 370
Macmahon, S., Bernstein, L., Macdonald, G., Andrews, G., & Blacket, R. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92310-4 · Cited by 365
When can a risk factor be used as a worthwhile screening test?
Wald, N. J., Hackshaw, A. K., & Frost, C. D. (1999) · BMJ · doi:10.1136/bmj.319.7224.1562 · Cited by 341
Self-citationHypertension Detection and Follow-up Program Cooperative Group* (1982) · New England Journal of Medicine · doi:10.1056/nejm198210143071603 · Cited by 338
Assessing possible hazards of reducing serum cholesterol
Law, M. R., Thompson, S. G., & Wald, N. J. (1994) · BMJ · doi:10.1136/bmj.308.6925.373 · Cited by 309
Self-citationThiazide Diuretic Agents and the Incidence of Hip Fracture
LaCroix, A. Z., Wienpahl, J., White, L. R., Wallace, R. B., Scherr, P. A., George, L. K., Cornoni-Huntley, J., & Ostfeld, A. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002013220502 · Cited by 299
Ethnic differences in incidence of stroke: prospective study with stroke register
Stewart, J. A., Dundas, R., Howard, R. S., Rudd, A. G., & Wolfe, C. D. A. (1999) · BMJ · doi:10.1136/bmj.318.7189.967 · Cited by 297
THE ROLE OF BLOOD-PRESSURE CONTROL IN PREVENTING COMPLICATIONS OF HYPERTENSION
Hamilton, M., Thompson, E. N., & Wisniewski, T. K. M. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92344-x · Cited by 293
Andersen, S., Tarnow, L., Rossing, P., Hansen, B. V., & Parving, H.-H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00880.x · Cited by 289
Malik, R. A., Williamson, S., Abbott, C., Carrington, A. L., Iqbal, J., Schady, W., & Boulton, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02478-7 · Cited by 284
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Pocock, S. J., McCormack, V., Gueyffier, F., Boutitie, F., Fagard, R. H., & Boissel, J.-P. (2001) · BMJ · doi:10.1136/bmj.323.7304.75 · Cited by 272
Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.
Carlsen, J. E., Køber, L., Torp-Pedersen, C., & Johansen, P. (1990) · BMJ · doi:10.1136/bmj.300.6730.975 · Cited by 269
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 268
Self-citationWITTEMAN, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91459-1 · Cited by 264
HYPOTENSIVE THERAPY IN STROKE SURVIVORS
Carter, A. B. (1970) · The Lancet · doi:10.1016/s0140-6736(70)91577-1 · Cited by 259
GLUCOSE INTOLERANCE IN HYPERTENSIVE PATIENTS TREATED WITH DIURETICS; A FOURTEEN-YEAR FOLLOW-UP
Murphy, M. B., Kohner, E., Lewis, P. J., Schumer, B., & Dollery, C. T. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91506-9 · Cited by 243
Apolipoproteins and ischaemic heart disease: implications for screening
Wald, N., Watt, H., Bailey, A., Johnson, M., Ledue, T. B., & Haddow, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90814-1 · Cited by 241
Self-citationD'Agostino, R. B., Belanger, A. J., Kannel, W. B., & Cruickshank, J. M. (1991) · BMJ · doi:10.1136/bmj.303.6799.385 · Cited by 239
Secondary prevention in coronary heart disease: baseline survey of provision in general practice
Campbell, N. C., Thain, J., Deans, H. G., Ritchie, L. D., & Rawles, J. M. (1998) · BMJ · doi:10.1136/bmj.316.7142.1430 · Cited by 236
GEOGRAPHICAL AND SECULAR TRENDS IN STROKE INCIDENCE
Malmgren, R., Bamford, J., Warlow, C., & Sandercock, P. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91331-6 · Cited by 236
MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Ni Mhurchu, C., Clark, T., Hart, H., Scott, J., & White, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00736-1 · Cited by 235
LONG-TERM USE OF THIAZIDE DIURETICS AND RISK OF HIP FRACTURE
Ray, W., Downey, W., Griffin, M., & Joseph Melton, L. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92205-8 · Cited by 232
Muir, J., Mant, D., Jones, L., & Yudkin, P. (1994) · BMJ · doi:10.1136/bmj.308.6924.308 · Cited by 231
Staessen, J., Bulpitt, C., Clement, D., De Leeuw, P., Fagard, R., Fletcher, A., Forette, F., Leonetti, G., Nissinen, A., & O'Malley, K. (1989) · BMJ · doi:10.1136/bmj.298.6687.1552 · Cited by 228
Gradman, A. H., Arcuri, K. E., Goldberg, A. I., Ikeda, L. S., Nelson, E. B., Snavely, D. B., & Sweet, C. S. (1995) · Hypertension · doi:10.1161/01.hyp.25.6.1345 · Cited by 226
Blood-pressure reduction and cardiovascular risk in HOPE study
Sleight, P., Yusuf, S., Pogue, J., Tsuyuki, R., Diaz, R., & Probstfield, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07186-0 · Cited by 219
Effects of modulators of the renin???angiotensin???aldosterone system on cough
Lacourci??re, Y., Brunner, H., Irwin, R., Karlberg, B. E., Ramsay, L. E., Snavely, D. B., Dobbins, T. W., Faison, E. P., & Nelson, E. B. (1994) · Journal of Hypertension · doi:10.1097/00004872-199412000-00012 · Cited by 216
The Underlying Risk of Death After Myocardial Infarction in the Absence of Treatment
Law, M. R., Watt, H. C., & Wald, N. J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.21.2405 · Cited by 216
Self-citationEpidemiology of Stroke in Innherred, Norway, 1994 to 1996: Incidence and 30-Day Case-Fatality Rate
Ellekjær, H., Holmen, J., Indredavik, B., & Terent, A. (1997) · Stroke · doi:10.1161/01.str.28.11.2180 · Cited by 215
Warlow, C. P. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301381 · Cited by 211
The Prognosis of Essential Hypertension Treated Conservatively
SOKOLOW, M., & PERLOFF, D. (1961) · Circulation · doi:10.1161/01.cir.23.5.697 · Cited by 201
Fatality outside hospital from acute coronary events in three British health districts, 1994-5
Group (1998) · BMJ · doi:10.1136/bmj.316.7137.1065 · Cited by 190
Potassium Supplementation in Hypertensive Patients with Diuretic-Induced Hypokalemia
Kaplan, N. M., Carnegie, A., Raskin, P., Heller, J. A., & Simmons, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503213121203 · Cited by 185
Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark.
Jørgensen, H. S., Plesner, A. M., Hübbe, P., & Larsen, K. (1992) · Stroke · doi:10.1161/01.str.23.12.1701 · Cited by 179
Prevention of End-Stage Renal Disease Due to Type 2 Diabetes
Hostetter, T. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451209 · Cited by 169
GIROUD, M., MILAN, C., BEURIAT, P., GRAS, P., ESSAYAGH, E., ARVEUX, P., & DUMAS, R. (1991) · International Journal of Epidemiology · doi:10.1093/ije/20.4.892 · Cited by 169
Long-term Effects on Plasma Lipids of Diet and Drugs to Treat Hypertension
Grimm, R. H. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440029033 · Cited by 168
Ramsay, L., Haq, I., Jackson, P., Yeo, W., Pickin, D., & Payne, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05516-x · Cited by 168
Kassler-Taub, K. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00491-3 · Cited by 168
Padwal, R., Straus, S. E., & McAlister, F. A. (2001) · BMJ · doi:10.1136/bmj.322.7292.977 · Cited by 166
Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91
Bonita, R., Broad, J. B., & Beaglehole, R. (1993) · The Lancet · doi:10.1016/0140-6736(93)92938-p · Cited by 164
Stroke Incidence and Case Fatality in Southern Greece: The Arcadia Stroke Registry
Vemmos, K. N., Bots, M. L., Tsibouris, P., Zis, V. P., Grobbee, D. E., Stranjalis, G., & Stamatelopoulos, S. F. (1999) · Stroke · doi:10.1161/01.str.30.2.363 · Cited by 153
The variability of measurements of casual blood pressure. II. Survey experience.
Armitage, P., Fox, W., Rose, G., & Tinker, C. M. (1966) · PubMed · Cited by 153
Frishman, W. H., Bryzinski, B. S., Coulson, L. R., DeQuattro, V. L., Vlachakis, N. D., Mroczek, W. J., Dukart, G., Goldberg, J. D., Alemayehu, D., & Koury, K. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130048008 · Cited by 152
Meta-analyses involving cross-over trials: methodological issues
Stedman, M. R., Curtin, F., Elbourne, D. R., Kesselheim, A. S., & Brookhart, M. A. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp345 · Cited by 148
Guidelines on preventing cardiovascular disease in clinical practice
Jackson, R. (2000) · BMJ · doi:10.1136/bmj.320.7236.659 · Cited by 143
Bulpitt, C. J. (1986) · Drugs · doi:10.2165/00003495-198600311-00007 · Cited by 142
MacKay, J. H., Arcuri, K. E., Goldberg, A. I., Snapinn, S. M., & Sweet, C. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030072009 · Cited by 140
Anderson, C. S., Chakera, T., Stewart‐Wynne, E. Q., Jamrozik, K. D., Burvill, P. W., & Johnson, G. A. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb137528.x · Cited by 140
Volmink, J. A., Newton, J. N., Hicks, N., Sleight, P., Fowler, G. H., & Neil, H. A. W. (1998) · Heart · doi:10.1136/hrt.80.1.40 · Cited by 139
High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study.
Helgeland, A., Hjermann, I., Leren, P., Enger, S. C., & Holme, I. (1978) · BMJ · doi:10.1136/bmj.2.6134.403 · Cited by 138
Lauria, G., Gentile, M., Fassetta, G., Casetta, I., Agnoli, F., Andreotta, G., Barp, C., Caneve, G., Cavallaro, A., Cielo, R., et al. (1995) · Stroke · doi:10.1161/01.str.26.10.1787 · Cited by 138
SEPIVAC: a community-based study of stroke incidence in Umbria, Italy.
Ricci, S., Celani, M. G., Rosa, F. L., Vitali, R., Duca, E., Ferraguzzi, R., Paolotti, M., Seppoloni, D., Caputo, N., & Chiurulla, C. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.8.695 · Cited by 136
Kaski, J. C., Rosano, G. M. C., Gavrielides, S., & Chen, L. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90750-1 · Cited by 133
Weir, M. R., Gray, J. M., Paster, R. Z., & Saunders, E. (1995) · Hypertension · doi:10.1161/01.hyp.26.1.124 · Cited by 133
Goldberg, M. R., Bradstreet, T. E., McWilliams, E. J., Tanaka, W. K., Lipert, S., Bjornsson, T. D., Waldman, S. A., Osborne, B., Pivadori, L., Lewis, G., et al. (1995) · Hypertension · doi:10.1161/01.hyp.25.1.37 · Cited by 129
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.
Perry, H. M., Smith, W. M., McDonald, R. H., Black, D. M., Cutler, J. A., Furberg, C. D., Greenlick, M. R., Kuller, L. H., Schnaper, H. W., & Schoenberger, J. A. (1989) · Stroke · doi:10.1161/01.str.20.1.4 · Cited by 129
The Asia Pacific Cohort Studies Collaboration
Woodward, M., & Martiniuk, A. L. C. (2003) · Cited by 127
Holwerda, N. J., Fogari, R., Angeli, P., Porcellati, C., Hereng, C., Oddou-Stock, P., Heath, R., & Bodin, F. (1996) · Journal of Hypertension · doi:10.1097/00004872-199609000-00016 · Cited by 124
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension
Kochar, M. S., Guthrie, R., Triscari, J., Kassler-Taub, K., & Reeves, R. A. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00053-9 · Cited by 123
Black, H., Graff, A., Shute, D., et al. (1997) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000482 · Cited by 120
Effect of thiazide on rates of bone mineral loss: a longitudinal study.
Wasnich, R. D., Davis, J., Ross, P. D., & Vogel, J. M. (1990) · BMJ · doi:10.1136/bmj.301.6764.1303 · Cited by 118
Benz, J., Black, H. R., Graff, A., Reed, A., Fitzsimmons, S., & Shi, Y. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000718 · Cited by 117
RE-EXAMINATION OF SOME OF THE FRAMINGHAM BLOOD-PRESSURE DATA
Anderson, T. W. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92288-2 · Cited by 115
Kontopoulos, A. G., Athyros, V. G., Didangelos, T., Papageorgiou, A. A., Avramidis, M. J., Mayroudi, M. C., & Karamitsos, D. T. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.355 · Cited by 113
Roberts, D. H., Mcloughlin, G., Tsao, Y., & Breckenridge, A. M. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92441-x · Cited by 109
1989 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH Meeting
&NA;, &. (1989) · Journal of Hypertension · doi:10.1097/00004872-198908000-00014 · Cited by 107
Declining Incidence and Mortality Rates of Stroke in Finland From 1972 to 1991
Numminen, H., Kotila, M., Waltimo, O., Aho, K., & Kaste, M. (1996) · Stroke · doi:10.1161/01.str.27.9.1487 · Cited by 105
Australian Therapeutic Trial in Mild Hypertension
Doyle, A. E. (1981) · Springer eBooks · doi:10.1007/978-1-4612-5899-5_6 · Cited by 102
Boden, W. E., van Gilst, W. H., Scheldewaert, R., Starkey, I. R., Carlier, M., Julian, D. G., Whitehead, A., Bertrand, M. E., Col, J. J., Pedersen, O. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02262-5 · Cited by 99
2005 Mortality statistics: cause (England and Wales).
(2007) · PubMed · Cited by 99
Benz, J. R., Oshrain, C., Henry, D. C., Avery, C., Chiang, Y., & Gatlin, M. R. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04767.x · Cited by 98
Weight and mortality in the Whitehall Study.
Jarrett, R. J., Shipley, M. J., & Rose, G. (1982) · BMJ · doi:10.1136/bmj.285.6341.535 · Cited by 98
TOTAL BODY AND SERUM POTASSIUM DURING PROLONGED THIAZIDE THERAPY FOR ESSENTIAL HYPERTENSION
Wilkinson, P. R., Hesp, R., Issler, H., & Raftery, E. B. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92432-0 · Cited by 97
Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial
Nueten, L. V., Taylor, F., & Robertson, J. I. S. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000571 · Cited by 94
Navis, G., Faber, H. J., de Zeeuw, D., & de Jong, P. E. (1996) · Drug Safety · doi:10.2165/00002018-199615030-00005 · Cited by 93
Effects of diuretic and beta-blocker therapy in the medical research council trial
Greenberg, G. M., Brennan, P. J., & Miall, W. E. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90956-2 · Cited by 92
Solomon, S. A., Ramsay, L. E., Yeo, W. W., Parnell, L. A., & Morris-Jones, W. (1991) · BMJ · doi:10.1136/bmj.303.6810.1100 · Cited by 92
EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL*
Neurath, H. M., Goldman, A. I., Lavin, M. A., Schnaper, H. W., Fitz, A. E., Frohlich, E. D., Steele, B. W., & Richman, H. G. (1978) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1978.tb25604.x · Cited by 91
Frishman, W. H., Ram, C. V. S., McMahon, F. G., Chrysant, S. G., Graff, A., Kupiec, J. W., & Hsu, H. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04027.x · Cited by 91
Blood Pressure and the Risk of Cardiovascular Disease
MacMahon, S. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001063420109 · Cited by 88
Thiazide Therapy Is Not a Cause of Arrhythmia in Patients With Systemic Hypertension
Papademetriou, V., Burris, J. F., Notargiacomo, A., Fletcher, R. D., & Freis, E. D. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380060036009 · Cited by 86
Rengo, F., Carbonin, P., Pahor, M., Caprio, L. D., Bernabei, R., Ferrara, N., Carosella, L., Acanfora, D., Parlati, S., Vitale, D. F., et al. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89365-4 · Cited by 86
Hypertension Detection and Follow-up Program Cooperative Group (1984) · Journal of Community Health · doi:10.1007/bf01338731 · Cited by 81
Berman, R., Anand, A., Cappiello, A., Miller, H., Hu, X. S., Oren, D. A., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00383-7 · Cited by 78
Psaty, B. M., Smith, N. L., Siscovick, D. S., Koepsell, T. D., Weiss, N. S., Heckbert, S. R., Lemaître, R. N., Wagner, E. H., & Furberg, C. D. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00059 · Cited by 76
Cheetham, C., O’Driscoll, G., STANTON, K. G., et al. (2000) · Clinical Science · doi:10.1042/cs1000013 · Cited by 74
Controlled study of atenolol in treatment of hypertension.
Hansson, L., Åberg, H., Karlberg, B. E., et al. (1975) · BMJ · doi:10.1136/bmj.2.5967.367 · Cited by 73
THE EFFECTS OF SPIRONOLACTONE AND CHLORTHALIDONE ON ARTERIAL PRESSURE
Cranston, W. I., & Juel‐Jensen, B. E. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92199-2 · Cited by 70
Paolisso, G., Tagliamonte, M. R., Gambardella, A., Manzella, D., Gualdiero, P., Varricchio, G., Verza, M., & Varricchio, M. (1997) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000434 · Cited by 65
Hansson, L. (1994) · Blood Pressure · doi:10.3109/08037059409102265 · Cited by 65
Kuschnir, E., Acuña, E., Sevilla, D., Vasquez, J., Bendersky, M., Resk, J., & Glazer, R. D. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80076-2 · Cited by 60
Püchler, K., Laeis, P., & Stumpe, K. O. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106001-00006 · Cited by 59
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours
Neutel, J., Weber, M. A., Pool, J. L., Smith, D., Fitzsimmons, S., Chiang, Y., & Gatlin, M. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80129-4 · Cited by 57
Nankervis, A. J., Nicholls, K., Kilmartin, G., Allen, P., Ratnaike, S., & Martin, F. I. R. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90364-x · Cited by 56
Frishman, W. H., Burris, J. F., Mroczek, W. J., Weir, M. R., Alemayehu, D., Simon, J. S., Chen, S. Y., & Bryzinski, B. S. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb05009.x · Cited by 56
Moxonidine and Hydrochlorothiazide in Combination: A Synergistic Antihypertensive Effect
Frei, M., Küster, L. J., von Krosigk, P.-P. G., et al. (1994) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199424001-00005 · Cited by 49
Myers, M. G., Asmar, R. G., Leenen, F. H. H., & Safar, M. E. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018030-00012 · Cited by 49
The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
Hedner, T., & Himmelmänn, A. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917010-00019 · Cited by 48
Fogari, R., Malacco, E., Tettamanti, F., Gnemmi, A. E., & Milani, M. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb05670.x · Cited by 48
Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen
Vanhees, L., Fagard, R., Lijnen, P., & Amery, A. (1991) · Journal of Hypertension · doi:10.1097/00004872-199111000-00013 · Cited by 47
Chrysant, S. G., Fagan, T., Glazer, R., & Kriegman, A. (1996) · Archives of Family Medicine · doi:10.1001/archfami.5.1.17 · Cited by 47
Cushman, W. C., Cohen, J. D., Jones, R. P., Marbury, T. C., Rhoades, R. B., & Smith, L. K. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00372-5 · Cited by 45
A dose-response trial of nebivolol in essential hypertension
Nueten, L. V., Dupont, A. G., Vertommen, C., Goyvaerts, H., & Robertson, J. I. S. (1997) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000392 · Cited by 45
Benetos, A., Gautier, S., Laflèche, A., Topouchian, J. A., Frangin, G., Girerd, X. J., Sissmann, J., & Safar, M. E. (2000) · Journal of Vascular Research · doi:10.1159/000025708 · Cited by 45
Pool, J. L., Cushman, W. C., Saini, R. K., Nwachuku, C. E., & Battikha, J. P. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(96)00323-8 · Cited by 45
Ferrara, L. A., SIMONE, G. D., Mancini, M., Fasano, M. L., Pasanisi, F., & Vallone, G. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00556886 · Cited by 44
Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension
Asmar, R. G., Kerihuel, J. C., Girerd, X. J., & Safar, M. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90711-s · Cited by 44
Headache in Mild-to-Moderate Hypertension and Its Reduction by Irbesartan Therapy
Hansson, L., Smith, D. H. G., Reeves, R., & Lapuerta, P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.11.1654 · Cited by 44
Lacourcière, Y., & Arnott, W. S. (1994) · PubMed · Cited by 43
Varying responses to hypotensive agents in different racial groups: black versus white differences
Seedat, Y. K. (1989) · Journal of Hypertension · doi:10.1097/00004872-198907000-00001 · Cited by 42
THE VARIABILITY OF MEASUREMENTS OF CASUAL BLOOD PRESSURE
Armitage, P., & Rose, G. A. (1967) · Survey of Anesthesiology · doi:10.1097/00132586-196706000-00004 · Cited by 42
Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II—receptor blocker
Pool, J. L., Oparil, S., Hedner, T., Glazer, R. D., Oddou-Stock, P., & Hester, A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80107-0 · Cited by 41
A community based stroke register in a high risk area for stroke in north west England.
Du, X. L., Sourbutts, J., Cruickshank, K. J., Summers, A., Roberts, N., Walton, E., & Holmes, S. (1997) · Journal of Epidemiology & Community Health · doi:10.1136/jech.51.5.472 · Cited by 38
McCorvey, E., Jt, W., Jp, C., Jm, M., Jd, P., & Mp, A. (1993) · PubMed · Cited by 38
Incidence of myocardial infarction in the Danish MONICA population 1982- 1991
Kirchhoff, M., Davidsen, M., Brønnum‐Hansen, H., Hansen, B., Schnack, H., Eriksen, L. S., Madsen, M., & Schroll, M. (1999) · International Journal of Epidemiology · doi:10.1093/ije/28.2.211 · Cited by 36
Haemodynamic effects and pharmacokinetics of oral d -and l -nebivolol in hypertensive patients
Himmelmänn, A., Hedner, T., Snoeck, E., et al. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050194 · Cited by 35
Christiansen, C., Christensen, M. S., Hagen, C., STOCKLUND, K., & Transbøl, I. (1981) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016348109154135 · Cited by 35
Gupta, R., Kjeldsen, S. E., Motley, E. D., Weder, A. B., Zweifler, A. J., & Julius, S. (1991) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199101000-00003 · Cited by 35
Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients
Merode, T. V., Bortel, L. M. V., Smeetst, F. A., Mooij, J. M. V., Böhm, R. O. B., Rahni, K. H., & Reneman, R. S. (1989) · Journal of Hypertension · doi:10.1097/00004872-198900076-00127 · Cited by 35
Morledge, J. H., Ettinger, B. B., Aranda, J. F., McBarron, F., Barra, P., Gorwit, J., & Davidov, M. E. (1986) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1986.tb04203.x · Cited by 33
Gradman, A. H., Gray, J. M., Maggiacomo, F., Punzi, H. A., & White, W. B. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88300-9 · Cited by 33
Effects of diltiazem or propranolol during exercise training of hypertensive men.
Stewart, K. J., Effron, M. B., Valenti, S. A., & Kelemen, M. H. (1990) · PubMed · Cited by 32
Effects of Verapamil and Trandolapril in the Treatment of Hypertension
Messerli, F. H., Frishman, W. H., & Elliott, W. J. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00466-4 · Cited by 32
Paster, R. Z., Snavely, D. B., Sweet, A. R., Draper, R. A., Goldberg, A. I., Soffer, B. A., & Sweet, C. S. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80079-9 · Cited by 32
Lopez, L. M., Thorman, A. D., & Mehta, J. L. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)91118-p · Cited by 31
Bisoprolol and Hypertension: Effects on Sexual Functioning in Men
Cp, B., Haensel, S. M., van de Ven, L. L. M., & Slob, A. K. (1992) · Journal of Sex & Marital Therapy · doi:10.1080/00926239208412857 · Cited by 31
Metformin and metoprolol CR treatment in non‐obese men
Landin‐Wilhelmsen, K., Tengborn, L., & Smith, U. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01083.x · Cited by 31
Effects of enalapril on mortality in severe congestive heart failure
(1988) · Journal of Cardiothoracic Anesthesia · doi:10.1016/0888-6296(88)90169-x · Cited by 31
Brown, C., Backhouse, C. I., Grippat, J. C., & Santoni, J. P. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315404 · Cited by 30
Atenolol and chlorthalidone in combination for hypertension.
Bateman, D. N., Dean, C., Mucklow, J., Bulpitt, C. J., & Dollery, C. T. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb00946.x · Cited by 30
Chalmers, J. P., Wing, L. M. H., West, M., Bune, A. J. C., Elliott, J. M., Morris, M. J., Cain, M. D., Graham, J. R., & Southgate, D. (1986) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1986.tb02014.x · Cited by 30
Tanser, P. H., Campbell, L. M., Carranza, J., Karrasch, J., Toutouzas, P. K., & Watts, R. W. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00165-x · Cited by 29
(2000) · Clinical cornerstone · doi:10.1016/s1098-3597(00)90033-4 · Cited by 28
T�tterman, K. J., Groop, L., Groop, P., Kala, R., Tolppanen, E. ‐., & Fyhrquist, F. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00546701 · Cited by 25
Antihypertensive and Metabolic Effects of Single and Combined Atenolol Regimens
Chrysant, S. G., Chappel, C., Farnham, D. J., Levin, B., Lueg, M. C., McCluskey, D., & STEINER, C. A. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03789.x · Cited by 25
Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients
Licata, G., Scaglione, R., Ganguzza, A., et al. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265946 · Cited by 25
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Bell, D. S. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430813 · Cited by 25
Jl, P. (1991) · PubMed · Cited by 25
Weir, M. R., Weber, M. A., Punzi, H. A., Serfer, H. M., Rosenblatt, S., & Cady, W. J. (1992) · PubMed · Cited by 24
Scholze, J. E., Zilles, P., & Compagnone, D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00708.x · Cited by 23
Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension
LEVINE, J., Ferdinand, K. C., Cargo, P., Laine, H., & Lefkowitz, M. P. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00053-r · Cited by 23
Whelton, A., Dunne, B., Glazer, N. M., Kostis, J. B., Miller, W. E., Rector, D. J., & Tresznewsky, O. N. (1992) · PubMed · Cited by 22
Pancera, P., Presciuttini, B., Sansone, S., Montagna, L., Paluani, F., Covi, G., & Lechi, A. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917040-00009 · Cited by 22
Chalmers, J. P., Wing, L. M. H., Grygiel, J. J., West, M., Graham, J. R., & Bune, A. J. C. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00545213 · Cited by 22
Neutel, J. M., Alderman, M. H., Anders, R. J., & Weber, M. A. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90464-0 · Cited by 22
Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients.
Fernández, M., Madero, R., González, D., Camacho, P., Villalpando, J., & Arriaga, J. J. (1994) · Hypertension · doi:10.1161/01.hyp.23.1_suppl.i207 · Cited by 21
Lisinopril administration improves insulin action in aged patients with hypertension.
Paolisso, G., Balbi, V., Gambardella, A., Varricchio, G., Tortoriello, R., Saccomanno, F., Amato, L., & Varricchio, M. (1995) · PubMed · Cited by 21
Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Franke, H. (1997) · PubMed · Cited by 21
Hedbäck, B., & Hermann, L. S. (1984) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1984.tb08687.x · Cited by 20
Kayanakis, J. G., & Baulac, L. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03127.x · Cited by 19
Influence of Beta‐Blocking Drugs on Glucose Metabolism in Hypertensive, Non‐Diabetic Patients
Groop, L., Tötterman, K. J., Harno, K., & Gordin, A. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb03681.x · Cited by 19
Bisoprolol, a once‐a‐day beta‐blocking agent for patients with mild to moderate hypertension
Davidov, M. E., Singh, S. P., Vlachakis, N. D., Blumenthal, J., Simon, J. S., Bryzinski, B. S., Koury, K. J., & Alemayehu, D. (1994) · Clinical Cardiology · doi:10.1002/clc.4960170509 · Cited by 19
Christensen, P. K., Lund, S. S., & Parving, H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00946.x · Cited by 19
Myers, M. G., & de Champlain, J. (1983) · Hypertension · doi:10.1161/01.hyp.5.4.591 · Cited by 19
Cited by
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
“As the reduction in blood pressure was not reported in most trials of people with a history of CHD, we estimated the average reduction from the average blood pressure before treatment and the average drug dose (as a multiple of standard dose”
BackgroundSelf-citationA strategy to reduce cardiovascular disease by more than 80%
Wald, N. J., & Law, M. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1419 · Cited by 1,568
Self-citationA Framework for Public Health Action: The Health Impact Pyramid
Frieden, T. R. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.185652 · Cited by 1,535
Fragala, M. S., Cadore, E. L., Dorgo, S., Izquierdo, M., Kraemer, W. J., Peterson, M. D., & Ryan, E. D. (2019) · Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003230 · Cited by 1,290
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Self-citation
Metadata
- Authors
- Law, M., Wald, N., & Morris, J.
- Venue
- Health Technology Assessment
- Published
- 2003-11
- Volume
- 7
- Issue
- 31
- Pages
- 1-94
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2107993459
- Cited by
- 327
- References
- 239
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.